III.J.34. Medical Countermeasures for Variola. Develop medical countermeasures against the biological warfare threat of variola, the causative agent of smallpox. By FY97, confirm the use of an animal model for the purpose of demonstrating the efficacy of the current licensed vaccine against aerosol-delivered variola. FY98, perform relevant preclinical testing of new cell culture-derived vaccinia vaccine directed towards variola. By FY99, develop rapid and highly specific diagnostic devices for clinical specimens. By FY00, explore the feasibility of using human monoclonal antibodies to replace vaccinia immune globulin (VIG). By FY01, screen and identify effective antiviral drugs for post-exposure treatment. Note: all of the studies conducted at USAMRIID will not utilize variola itself, instead the studies will employ the use of an appropriate orthopox virus substitute.
|STO Manager:||TSO:||TRADOC POC:|
|Dr. Anna Johnson-Winegar||MAJ Mark Seymour||CPT Ensor|